Table 2.
Results | Primary outcomes | Subgroup analyses | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
28 days | 90 days | ICU | Hospital | Low risk | High risk | VP | VP analogs | AT-II | Refractory shock | Septic shock | |
RR | 0.92 | 0.95 | 0.96 | 1.08 | 0.91 | 0.97 | 0.95 | 0.91 | 0.85 | 0.84 | 0.94 |
95% CI lower bound | 0.86 | 0.88 | 0.77 | 0.92 | 0.84 | 0.83 | 0.85 | 0.81 | 0.69 | 0.70 | 0.87 |
95% CI upper bound | 0.99 | 1.04 | 1.20 | 1.27 | 0.98 | 1.15 | 1.06 | 1.02 | 1.06 | 0.998 | 1.01 |
P value | 0.02* | 0.26 | 0.73 | 0.35 | 0.02* | 0.75 | 0.33 | 0.11 | 0.14 | 0.048* | 0.11 |
ICU intensive care unit, VP vasopressin, AT-II angiotensin II, RR relative risk, CI confidence interval, *P < 0.05